Andelen af patienter, som responderede i Arava- gruppen, var mellem 49 og 55% sammenlignet med 26 til 28% for patienter, der modtog placebo, og 54% for patienter, der modtog sulphasalazin.
The proportion of responders in the Arava group was between 49 and 55%, compared with 26 to 28% for patients taking placebo, and 54% for patients taking sulphasalazine.